Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) CFO Frank Stokes sold 6,923 shares of the business's stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $29.93, for a total value of $207,205.39. Following the transaction, the chief financial officer now owns 30,823 shares of the company's stock, valued at approximately $922,532.39. This represents a 18.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Castle Biosciences Stock Performance
CSTL opened at $28.87 on Wednesday. The company has a market capitalization of $808.65 million, a price-to-earnings ratio of 144.36 and a beta of 0.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. Castle Biosciences, Inc. has a 1-year low of $16.97 and a 1-year high of $35.84. The business has a 50 day moving average price of $31.10 and a two-hundred day moving average price of $26.39.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.14. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. The company had revenue of $85.78 million during the quarter, compared to the consensus estimate of $78.55 million. During the same quarter in the prior year, the firm earned ($0.26) EPS. Research analysts predict that Castle Biosciences, Inc. will post -0.08 EPS for the current fiscal year.
Institutional Investors Weigh In On Castle Biosciences
This Bull Market Indicator called NVDA at $116
From WealthPress | Ad
Every now and again we find an investment idea so incredible we can’t help but share.
And today is one of those rare days…
Except, today we won't be giving you insight on any one particular stock…
But rather, insight on a revolutionary new stock picking indicator…
In fact, within the last year, this indicator has become famous for a multitude of reasons…
But one of the biggest was because of the buy signal it issued on October 18th, 2022.
In fact, on that very day, it said to buy NVDA at $116.37…
Anyone who did would be sitting on a tremendously large return today…
But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
All you have to do is follow this link here
A number of institutional investors and hedge funds have recently modified their holdings of CSTL. State Board of Administration of Florida Retirement System acquired a new stake in shares of Castle Biosciences during the 1st quarter valued at $249,000. Vanguard Group Inc. lifted its position in shares of Castle Biosciences by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 1,494,176 shares of the company's stock valued at $33,096,000 after acquiring an additional 32,695 shares during the last quarter. Acadian Asset Management LLC raised its stake in Castle Biosciences by 130.7% during the 1st quarter. Acadian Asset Management LLC now owns 210,824 shares of the company's stock valued at $4,669,000 after purchasing an additional 119,443 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Castle Biosciences by 6.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 18,034 shares of the company's stock valued at $400,000 after purchasing an additional 1,131 shares during the period. Finally, Harbor Capital Advisors Inc. raised its stake in Castle Biosciences by 249.3% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 138,707 shares of the company's stock valued at $3,020,000 after purchasing an additional 99,001 shares during the period. Institutional investors and hedge funds own 92.60% of the company's stock.
Analysts Set New Price Targets
Several brokerages have recently issued reports on CSTL. Robert W. Baird boosted their price objective on Castle Biosciences from $37.00 to $39.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 5th. Scotiabank boosted their price objective on Castle Biosciences from $37.00 to $44.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, November 6th. Canaccord Genuity Group boosted their price objective on Castle Biosciences from $35.00 to $42.00 and gave the stock a "buy" rating in a research report on Tuesday, October 29th. Lake Street Capital boosted their price objective on Castle Biosciences from $34.00 to $40.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Finally, KeyCorp boosted their price objective on Castle Biosciences from $28.00 to $36.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $37.88.
View Our Latest Stock Report on Castle Biosciences
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
